2023 European Society of Cardiology Clinical Practice Guidelines
The 2023 ESC Guidelines represent a comprehensive update to the diagnosis and management of cardiomyopathies, incorporating new evidence and diagnostic approaches:
The ESC guideline approach emphasizes phenotype-based classification, which groups cardiomyopathies by their distinctive morphological and functional characteristics.
Key Features: Asymmetric septal hypertrophy, LVOT obstruction (~30%), systolic anterior motion of mitral valve, risk of sudden cardiac death
Genetics: Autosomal dominant; sarcomeric gene mutations
Key Features: Systolic dysfunction, chamber enlargement, increased heart failure and arrhythmia risk
Genetics: Autosomal dominant (40-50%), diverse gene mutations
Key Features: Ventricular arrhythmias (LBBB pattern), fatty infiltration, high SCD risk
Genetics: Autosomal dominant; desmosomal gene mutations
Key Features: Restrictive filling, biatrial enlargement, may be associated with amyloidosis (AL, ATTRwt, ATTRv)
Genetics: Systemic causes more common than isolated genetic forms
Key Features: Regional wall motion abnormalities, normal chamber size despite systolic dysfunction, often missed diagnosis
Genetics: Sarcomeric and non-sarcomeric mutations identified
A systematic multimodality approach is essential for accurate cardiomyopathy diagnosis, risk stratification, and management planning.
Detailed history (symptoms, family history), physical examination, and 12-lead ECG to identify hypertrophy patterns, conduction abnormalities, and arrhythmia markers
Comprehensive 2D and Doppler assessment of chamber dimensions, wall thickness, systolic and diastolic function, valve pathology, and LVOT obstruction
Indicated for tissue characterization (LGE pattern), detection of fibrosis, RV assessment, and clarification of uncertain diagnoses
Consider when diagnosis confirmed, family history present, or phenotype suggestive of genetic cardiomyopathy
Late gadolinium enhancement patterns are highly specific for cardiomyopathy phenotypes and provide prognostic information:
Genetic testing is integral to cardiomyopathy diagnosis, family screening, and management decisions.
Step 1 (Proband Testing): Confirm diagnosis through genetic testing when clinically indicated
Step 2 (Family Communication): Communicate results to family; offer genetic counseling
Step 3 (Cascade Testing): First-degree relatives offered predictive genetic testing for identified pathogenic variant
Step 4 (Cardiac Screening): Annual ECG and echocardiography for mutation carriers (ages 10-30)
Step 5 (Risk Stratification): Management decisions based on phenotypic expression and SCD risk
HCM management focuses on symptom relief, LVOT obstruction prevention, heart failure management, and SCD prevention.
Beta-blockers: First-line agents for symptom relief; reduce contractility and heart rate response.
Class IIaNon-dihydropyridine CCBs: Alternative to beta-blockers when contraindicated or not tolerated.
Peak systolic gradient: Resting <30 mmHg, Provoked ≥30 mmHg, or ≥50 mmHg warrants intervention consideration
Class I Beta-blockers or non-dihydropyridine CCBs to reduce contractility
Class IIa Add disopyramide if inadequate symptom relief with single agent
Class I Percutaneous or surgical septal reduction for symptomatic patients despite optimal medical therapy with gradient ≥50 mmHg
DCM management follows guideline-directed medical therapy (GDMT) principles, with emphasis on neurohormonal antagonism and device therapy.
ACE Inhibitors or ARBs: First-line therapy for all DCM patients with reduced LVEF.
Class IBeta-blockers: Reduce mortality and hospitalizations; titrate to target doses.
Class IMineralocorticoid Receptor Antagonists: Spironolactone or eplerenone for symptomatic patients.
Class IIaARNI (Sacubitril/Valsartan): Alternative to ACEi/ARB for improved outcomes.
Class IIaSGLT2 Inhibitors: Emerging evidence for mortality/hospitalization reduction.
| Device Therapy | Indications | Class |
|---|---|---|
| ICD (Primary Prevention) | LVEF ≤35% on optimal GDMT for ≥40 days | Class I |
| ICD (Secondary Prevention) | Sustained VT/VF despite optimal therapy | Class I |
| CRT (±D) | QRS ≥120 ms, LVEF ≤35%, NYHA II-IV symptoms | Class I |
| Mechanical Support | LVEF <25-30%, inotrope-dependent state | Class IIa |
ARVC management emphasizes arrhythmia prevention, SCD risk stratification, and ICD therapy.
Class I Sotalol or amiodarone for sustained VT/ventricular fibrillation
Class I ICD indicated for sustained VT/VF with hemodynamic impact or multiple ICD therapies
Class IIa Consider ICD in asymptomatic patients with extensive RV involvement and SCD risk markers
Restrictive cardiomyopathy (RCM) represents a heterogeneous group with restrictive physiology. Cardiac amyloidosis (AL, ATTRwt, ATTRv) requires specific diagnosis and therapy.
Restrictive physiology, biatrial enlargement, low QRS voltage, HFpEF
Diffuse subendocardial or transmural LGE; apical sparing may occur
Class I Endomyocardial biopsy with Congo red staining for confirmation
AL (light chain) vs ATTR (transthyretin): genetic testing, immunofluorescence, mass spectrometry
AL Amyloidosis: Chemotherapy (bortezomib-based) with or without autologous stem cell transplantation
Class IIaATTRwt: Tafamidis (kinetic stabilizer) reduces mortality and hospitalizations in HFpEF-amyloid
Class IIaATTRv: Tafamidis or diflunisal in early disease
SCD risk stratification in cardiomyopathies integrates multiple clinical, imaging, genetic, and electrophysiologic markers.
High-Risk Features (Consider ICD):
Class I ICD indicated in HCM with one or more high-risk markers
| Clinical Scenario | ICD Indication | Class |
|---|---|---|
| LVEF ≤35% on optimal GDMT ≥40 days | Primary prevention | Class I |
| Prior sustained VT/VF episode | Secondary prevention | Class I |
| Awaiting heart transplantation | Bridge therapy | Class I |
| LVEF 36-40% with NSVT/inducible VT | Individual assessment | Class IIa |
Appropriate exercise guidance is critical for maintaining quality of life while minimizing SCD risk.
Pregnancy poses unique challenges in cardiomyopathy patients. Careful risk stratification and multidisciplinary management are essential.
High-Risk Features:
Class I Preconception counseling for all women with cardiomyopathy
Class I Multidisciplinary team management for high-risk pregnancies
Class I Standard HF therapy (diuretics, inotropes, vasodilators)
30-50% of PPCM patients achieve complete or near-complete recovery; prognosis improves with early recognition
Atrial fibrillation is common in cardiomyopathies and carries significant mortality and morbidity risk.
All cardiomyopathy patients with AF require anticoagulation to prevent thromboembolic events:
| Strategy | Agents | Indications |
|---|---|---|
| Rate Control | Beta-blockers, diltiazem, verapamil, digoxin | Most cardiomyopathy patients; reduced LVEF |
| Rhythm Control | Amiodarone, sotalol, dofetilide | Symptomatic refractory to rate control |
| Catheter Ablation | PVI ± substrate modification | Symptomatic AF despite medical therapy |
Risk assessment and decision support tools relevant to cardiomyopathy management:
ESC 5-year sudden cardiac death risk calculator for hypertrophic cardiomyopathy — guides ICD implantation decisions.
2010 Task Force criteria scoring for arrhythmogenic right ventricular cardiomyopathy diagnosis.
Heart failure mortality prediction in dilated and ischemic cardiomyopathy.
Guideline-based ICD assessment for primary prevention in non-ischemic and ischemic cardiomyopathy.
QTc correction for antiarrhythmic drug monitoring in cardiomyopathy patients.
Heart failure guideline-directed medical therapy assessment and optimization tracking.